Peroxisome proliferator activated receptor γ and oxidized docosahexaenoic acids as new class of ligand

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 377, Issue 4-6, 2008, Pages 541-547

  Itoh, Toshimasa ^a   Yamamoto, Keiko ^b  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b SHOWA PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Atherosclerosis; Diabetes; Docosahexaenoic acid; Drug design; Fish oil; Inflammation; Oxidized docosahexaenoic acid; PPAR

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 4 HYDROXYDOCOSAHEXAENOIC ACID; 4 OXODOCOSAHEXAENOIC ACID; ANTIDIABETIC AGENT; CARBOPLATIN; DOCOSAHEXAENOIC ACID; N (2 BENZOYLPHENYL) O [2 (METHYL 2 PYRIDINYLAMINO)ETHYL]TYROSINE; OXIDIZED DOCOSAHEXAENOIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; ROSIGLITAZONE; TROGLITAZONE;

ATHEROSCLEROSIS; BONE TURNOVER; CONFERENCE PAPER; DIABETES MELLITUS; DRUG SCREENING; DRUG SYNTHESIS; DRUG TARGETING; EDEMA; ENCEPHALITIS; ENTERITIS; HEART INFARCTION; HUMAN; HYDROPHILICITY; IN VITRO STUDY; NEOPLASM; NONHUMAN; OBESITY; PROTEIN TARGETING; STRUCTURE ACTIVITY RELATION;

ANIMALS; DOCOSAHEXAENOIC ACIDS; DRUG DELIVERY SYSTEMS; GENE EXPRESSION REGULATION; HUMANS; HYPOGLYCEMIC AGENTS; LIGANDS; OXIDATION-REDUCTION; PPAR GAMMA; THIAZOLIDINEDIONES;

EID: 45849140905     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00210-007-0251-x     Document Type: Conference Paper

References (49)

1. Babaev VR, Yancey PG, Ryzhov SV, Kon V, Breyer MD, Magnuson MA, Fazio S, Linton MF (2005) Conditional knockout of macrophage PPARγ increases atherosclerosis in C57BL/6 and low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 25:1647-1653
2. Baylis C, Atzpodien EA, Freshour G, Engels K (2003) Peroxisome proliferator-activated receptorγ agonist provides superior renal protection versus angiotensin-converting enzyme inhibition in a rat model of type 2 diabetes with obesity. J Pharmacol Exp Ther 307:854-860
3. Benkirane K, Amiri F, Diep QN, El Mabrouk M, Schiffrin EL (2006) PPAR-gamma inhibits ANG II-induced cell growth via SHIP2 and 4E-BP1. Am J Physiol Heart Circ Physiol 290:H390-H397
4. Berk BC, Haendeler J, Sottile J (2000) Angiotensin II, atherosclerosis, and aortic aneurysms. J Clin Invest 105:1525-1526
5. Bernardo A, Ajmone-Cat MA, Gasparini L, Ongini E, Minghetti L (2005) Nuclear receptor peroxisome proliferator-activated receptorγ is activated in rat microglial cells by the anti-inflammatory drug HCT1026, a derivative of flurbiprofen. J Neurochem 92:895-903
6. Bishop-Bailey D, Hla T (1999) Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Δ2, 14-prostaglandin J2. J Biol Chem 274:17042-17048
7. Calkin AC, Forbes JM, Smith CM, Lassila M, Cooper ME, Jandeleit-Dahm KA, Allen TJ (2005) Rosiglitazone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects. Arterioscler Thromb Vasc Biol 25:1903-1909
8. Combs CK, Johnson DE, Karlo JC, Cannady SB, Landreth GE (2000) Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J Neurosci 20:558-567
9. Cronet P, Petersen JF, Folmer R, Blomberg N, Sjoblom K, Karlsson U, Lindstedt EL, Bamberg K (2001) Structure of the PPARα and -γ ligand binding domain in complex with AZ242; ligand selectivity and agonist activation in the PPAR family. Structure 9:699-706
10. Cuzzocrea S, Pisano B, Dugo L, Ianaro A, Patel NS, Di Paola R, Genovese T, Chatterjee PK, Di Rosa M, Caputi AP, Thiemermann C (2003) Rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2, ligands of the peroxisome proliferator-activated receptorγ (PPARγ), reduce ischaemia/reperfusion injury of the gut. Br J Pharmacol 140:366-376
11. Demetri GD, Fletcher CD, Mueller E, Sarraf P, Naujoks R, Campbell N, Spiegelman BM, Singer S (1999) Induction of solid tumor differentiation by the peroxisome proliferator-activated receptorγ ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci USA 96:3951-3956
12. Diau GY, Hsieh AT, Sarkadi-Nagy EA, Wijendran V, Nathanielsz PW, Brenna JT (2005) The influence of long chain polyunsaturate supplementation on docosahexaenoic acid and arachidonic acid in baboon neonate central nervous system. BMC Med 3:11
13. Drori S, Girnun GD, Tou L, Szwaya JD, Mueller E, Xia K, Shivdasani RA, Spiegelman BM (2005) Hic-5 regulates an epithelial program mediated by PPARγ. Genes Dev 19:362-375
14. Dubuquoy L, Rousseaux C, Thuru X, Peyrin-Biroulet L, Romano O, Chavatte P, Chamaillard M, Desreumaux P (2006) PPARγ as a new therapeutic target in inflammatory bowel diseases. Gut 55:1341-1349
15. Fajas L, Auboeuf D, Raspe E, Schoonjans K, Lefebvre AM, Saladin R, Najib J, Laville M, Fruchart JC, Deeb S, Vidal-Puig A, Flier J, Briggs MR, Staels B, Vidal H, Auwerx J (1997) The organization, promoter analysis, and expression of the human PPARγ gene. J Biol Chem 272:18779-18789
16. Gampe RT Jr, Montana VG, Lambert MH, Miller AB, Bledsoe RK, Milburn MV, Kliewer SA, Willson TM, Xu HE (2000) Asymmetry in the PPARγ/RXRγ crystal structure reveals the molecular basis of heterodimerization among nuclear receptors. Mol Cell 5:545-555
17. Giaginis C, Tsantili-Kakoulidou A, Theocharis S (2007) Peroxisome proliferator-activated receptors (PPARs) in the control of bone metabolism. Fundam Clin Pharmacol 21:231-244
18. Girnun GD, Naseri E, Vafai SB, Qu L, Szwaya JD, Bronson R, Alberta JA, Spiegelman BM (2007) Synergy between PPARγ ligands and platinum-based drugs in cancer. Cancer Cell 11:395-406
19. Giulian D (1999) Microglia and the immune pathology of Alzheimer disease. Am J Hum Genet 65:13-18
20. Hirsch EC, Breidert T, Rousselet E, Hunot S, Hartmann A, Michel PP (2003) The role of glial reaction and inflammation in Parkinson's disease. Ann N Y Acad Sci 991:214-228
21. Itagaki S, McGeer PL, Akiyama H, Zhu S, Selkoe D (1989) Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. J Neuroimmunol 24:173-182
22. Itoh T, Murota I, Yoshikai K, Yamada S, Yamamoto K (2006) Synthesis of docosahexaenoic acid derivatives designed as novel PPARγ agonists and antidiabetic agents. Bioorg Med Chem 14:98-108
23. Kintscher U, Lyon CJ, Law RE (2004) Angiotensin II, PPAR-gamma and atherosclerosis. Front Biosci 9:359-369
24. Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehmann JM (1995) A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 83:813-819
25. Kulke MH, Demetri GD, Sharpless NE, Ryan DP, Shivdasani R, Clark JS, Spiegelman BM, Kim H, Mayer RJ, Fuchs CS (2002) A phase II study of troglitazone, an activator of the PPARg receptor, in patients with chemotherapy-resistant metastatic colorectal cancer. Cancer J 8:395-399
26. Landreth GE, Heneka MT (2001) Anti-inflammatory actions of peroxisome proliferator-activated receptor gamma agonists in Alzheimer's disease. Neurobiol Aging 22:937-944
27. Lyseng-Williamson KA (2007) Sitagliptin: a guide to its use in type 2 diabetes. Drugs 67:587-597
28. Mudaliar S, Henry RR (2001) New oral therapies for type 2 diabetes mellitus: the glitazones or insulin sensitizers. Annu Rev Med 52:239-257
29. Murata T, He S, Hangai M, Ishibashi T, Xi XP, Kim S, Hsueh WA, Ryan SJ, Law RE, Hinton DR (2000) Peroxisome proliferator-activated receptorγ ligands inhibit choroidal neovascularization. Invest Ophthalmol Vis Sci 41:2309-2317
30. Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356:2457-2471
31. Nolte RT, Wisely GB, Westin S, Cobb JE, Lambert MH, Kurokawa R, Rosenfeld MG, Willson TM, Glass CK, Milburn MV (1998) Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptorγ. Nature 395:137-143
32. Panigrahy D, Singer S, Shen LQ, Butterfield CE, Freedman DA, Chen EJ, Moses MA, Kilroy S, Duensing S, Fletcher C, Fletcher JA, Hlatky L, Hahnfeldt P, Folkman J, Kaipainen A (2002) PPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest 110:923-932
33. Patel CB, De Lemos JA, Wyne KL, McGuire DK (2006) Thiazolidinediones and risk for atherosclerosis: pleiotropic effects of PPARγ agonism. Diab Vasc Dis Res 3:65-71
34. Rousseaux C, Lefebvre B, Dubuquoy L, Lefebvre P, Romano O, Auwerx J, Metzger D, Wahli W, Desvergne B, Naccari GC, Chavatte P, Farce A, Bulois P, Cortot A, Colombel JF, Desreumaux P (2005) Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptorγ. J Exp Med 201:1205-1215
35. Rzonca SO, Suva LJ, Gaddy D, Montague DC, Lecka-Czernik B (2004) Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 145:401-406
36. Sanchez-Hidalgo M, Martin AR, Villegas I, Alarcon De La Lastra C (2005) Rosiglitazone, an agonist of peroxisome proliferator-activated receptorγ, reduces chronic colonic inflammation in rats. Biochem Pharmacol 69:1733-1744
37. Sassa Y, Hata Y, Aiello LP, Taniguchi Y, Kohno K, Ishibashi T (2004) Bifunctional properties of peroxisome proliferator-activated receptorγ1 in KDR gene regulation mediated via interaction with both Sp1 and Sp3. Diabetes 53:1222-1229
38. Schwartz AV, Sellmeyer DE, Vittinghoff E, Palermo L, Lecka-Czernik B, Feingold KR, Strotmeyer ES, Resnick HE, Carbone L, Beamer BA, Park SW, Lane NE, Harris TB, Cummings SR (2006) Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 91:3349-3354
39. Staels B (2005) PPARγ and atherosclerosis. Curr Med Res Opin 21(Suppl 1):S13-S20
40. Sugawara K, Olson TS, Moskaluk CA, Stevens BK, Hoang S, Kozaiwa K, Cominelli F, Ley KF, McDuffie M (2005) Linkage to peroxisome proliferator-activated receptorγ in SAMP1/YitFc mice and in human Crohn's disease. Gastroenterology 128:351-360
41. Suzuki S, Akechi T, Kobayashi M, Taniguchi K, Goto K, Sasaki S, Tsugane S, Nishiwaki Y, Miyaoka H, Uchitomi Y (2004) Daily omega-3 fatty acid intake and depression in Japanese patients with newly diagnosed lung cancer. Br J Cancer 90:787-793
42. Tontonoz P, Singer S, Forman BM, Sarraf P, Fletcher JA, Fletcher CD, Brun RP, Mueller E, Altiok S, Oppenheim H, Evans RM, Spiegelman BM (1997) Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptorγ and the retinoid X receptor. Proc Natl Acad Sci U S A 94:237-241
43. Vanden Heuvel JP (2007) The PPAR resource page. Biochim Biophys Acta 1771:1108-1112
44. Wang T, Xu J, Yu X, Yang R, Han ZC (2006) Peroxisome proliferator- activated receptorγ in malignant diseases. Crit Rev Oncol Hematol 58:1-14
45. Xin X, Yang S, Kowalski J, Gerritsen ME (1999) Peroxisome proliferator-activated receptorγ ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem 274:9116-9121
46. Xu HE, Lambert MH, Montana VG, Plunket KD, Moore LB, Collins JL, Oplinger JA, Kliewer SA, Gampe RT Jr, McKee DD, Moore JT, Willson TM (2001) Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors. Proc Natl Acad Sci U S A 98:13919-13924
47. Yamamoto K, Sun WY, Ohta M, Hamada K, DeLuca HF, Yamada S (1996) Conformationally restricted analogs of 1α,25-dihydroxyvitamin D3 and Its 20-epimer: compounds for study of the three-dimensional structure of vitamin d responsible for binding to the receptor. J Med Chem 39:2727-2737
48. Yamamoto K, Itoh T, Abe D, Shimizu M, Kanda T, Koyama T, Nishikawa M, Tamai T, Ooizumi H, Yamada S (2005) Identification of putative metabolites of docosahexaenoic acid as potent PPARγ agonists and antidiabetic agents. Bioorg Med Chem Lett 15:517-522
49. Yli-Jama P, Meyer HE, Ringstad J, Pedersen JI (2002) Serum free fatty acid pattern and risk of myocardial infarction: a case-control study. J Intern Med 251:19-28